

Most recent changes to the CPT[®] Category I New Immunization* Vaccine Codes Long Descriptor document:

- Correct "Revised Code Effective" date from May 1, 2023 to April 18, 2023 for code 0164A.

It is important to note that further CPT Editorial Panel or Executive Committee actions may affect these codes and/or descriptors. For this reason, code numbers and/or descriptor language in the CPT code set may differ at the time of publication. In addition, further Panel actions" may result in gaps in code number sequencing.

The removal of the FDA pending symbol follows notification that this product had been granted FDA approval status on the date indicated. Code 90678 was originally published in CPT 2023.

Codes	Long Descriptor	Released to AMA Website	FDA Approval Effective	Publication
≠ 90678	Respiratory syncytial virus vaccine, preF, subunit, bivalent, for intramuscular use	June 30, 2023	May 31, 2023	CPT® 2024

The following vaccine codes were accepted at the July 2022 CPT Editorial Panel meeting for the 2024 CPT production cycle. These codes are effective immediately on July 26, 2022.

*Note that code 90611 will follow code 90713 and code 90622 will follow code 90627.

Codes	Long Descriptor	Released to AMA Website	Effective	Publication
# • 90611	Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, non-replicating, preservative free, 0.5 mL dosage, suspension, for subcutaneous use	July 26, 2022	July 26, 2022	CPT [®] 2024
#●90622	Vaccinia (smallpox) virus vaccine, live, lyophilized, 0.3 mL dosage, for percutaneous use	July 26, 2022	July 26, 2022	CPT [®] 2024

The following vaccine codes were accepted at the February 2023 CPT Editorial Panel meeting for the 2024 CPT production cycle. Code 90679 was effective immediately on May 3, 2023. Codes 90589, 90623 are effective on January 1, 2024.

*Note that code 90589 will follow code 90586 and code 90623 will follow 90619.

Codes	Long Descriptor	Released to AMA Website	Effective	Publication
#№●90589	Chikungunya virus vaccine, live attenuated, for intramuscular use	June 30, 2023	January 1, 2024	CPT [®] 2024
# № ●90623	Meningococcal pentavalent vaccine, conjugated Men A, C, W, Y- tetanus toxoid carrier, and Men B-FHbp, for intramuscular use	June 30, 2023	January 1, 2024	CPT [®] 2024

^{*}For the purposes of CPT coding, "Immunization" includes vaccines/toxoids, immune globulins, serum or recombinant products.



●90679	Respiratory syncytial virus vaccine, preF, recombinant, subunit, adjuvanted, for intramuscular use	May 5, 2023	May 3, 2023	CPT [®] 2024

The following immunization codes were accepted at the May 2023 CPT Editorial Panel meeting for the 2024 CPT production cycle. Codes 90380, 90381 was effective immediately on July 17, 2023. Code 90683 is effective on January 1, 2024.

*Note that code 90683 will follow code 90679.

Codes	Long Descriptor	Released to AMA Website	Effective	Publication
≠ ●90380	Respiratory syncytial virus, monoclonal antibody, seasonal dose; 0.5 mL dosage, for intramuscular use	June 30, 2023	July 17, 2023	CPT [®] 2024
≠ ●90381	1 mL dosage, for intramuscular use	June 30, 2023	July 17, 2023	CPT [®] 2024
# № ●90683	Respiratory syncytial virus vaccine, mRNA lipid nanoparticles, for intramuscular use	June 30, 2023	January 1, 2024	CPT [®] 2024



The following codes were accepted by the CPT Editorial Panel. Codes 0001A, 0002A, and 91300 are effective December 11, 2020. Codes 0011A, 0012A, and 91301 are effective December 18, 2020. Codes 0031A and 91303 are effective February 27, 2021. Revised code 0031A is effective October 20, 2021. Codes 0003A and 0013A are effective August 12, 2021. Code 0004A is effective on September 22, 2021. Codes 0034A, 0064A, and 91306 are effective October 20, 2021. Codes 0051A, 0052A, 0053A, 0054A, 0071A, 0072A, 91305, and 91307 are effective October 29, 2021. Code 0073A is effective January 3, 2022. Codes 0094A and 91309 are effective March 29, 2022. Code 0074A is effective May 17, 2022. Codes 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0111A, 0112A, 0113A, 91308, and 91311 are effective June 17, 2022. Revised code 0094A is effective July 6, 2022. Codes 0041A, 0042A, and 91304 are effective July 13, 2022. Codes 0124A and 91312 are effective August 31, 2022. Codes 0134A and 91313 are effective August 31, 2022 for patient aged 18 years and older. Codes 0134A (12 years through 17 years), 0144A, 0154A, 91313 (12 years through 17 years), 91314, and 91315 are effective October 12, 2022. Code 0044A is effective October 19, 2022. Codes 0164A, 0173A, 91316, and 91317 are effective December 8, 2022. Revised code 0173A and new code 0174A are effective March 14, 2023. Revised codes 0124A, 0134A, 0144A, 0154A, 0164A, 0173A, 0174A and new codes 0121A, 0141A, 0142A, 0151A, 0171A, 0172A are effective April 18, 2023.

Codes 0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0111A, 0112A, 0113A, 91300, 91301, 91305, 91306, 91307, 91308, 91309, and 91311 are no longer authorized for use in the United States as of April 18, 2023.

Codes 0031A, 0034A, and 91303 are no longer authorized for use in the United States as of June 1, 2023.

Codes 0021A, 0022A, 0104A, 91302, and 91310 will be effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration.

*Note codes 0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0104A, 0111A, 0112A, 0113A, and resequenced codes 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A will follow code 90474. Resequenced codes 91300, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309, 91310, 91311, 91312, 91313, 91314, 91315, 91316 and 91317 will precede code 90476.

des	Long Descriptor	Released to AMA Website	Effective	Publication
	Evaluation and Management Preventive Medicine Services Vaccine/toxoid products, immunization administrations,	Revised Guidelines Released to AMA Website	New and Revised Guidelines Effective	New and Revised Guidelines Publication
	ancillary studies involving laboratory, radiology, other procedures, or screening tests (eg, vision, hearing,	November 10, 2020	0071A, 0072A, 91305, 91307;	CPT®
	developmental) identified with a specific CPT code are reported separately. For immunization administration and	December 17, 2020	October 29, 2021	2022/2023/2024
	vaccine risk/benefit counseling, see 90460, 90461, 90471-90474, 0001A, 0002A, 0003A, 0004A, 0011A, 0012A,	January 19, 2021	0073A: January 3,	
	0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A,	March 1, 2021	2022	
	0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A,	May 4, 2021	0094A, 91309: March 29, 2022	
	0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A. For	July 30, 2021	0074A: May 17, 2022	
	vaccine/toxoid products, see 90476-90759, 91300- 91317 91316913159131191310, 91301, 91302, 91303,	August 16, 2021	0081A, 0082A,	
	91304 <u>, 91305</u> , 91306, 91307, 91308, 91309. ◀	September 3, 2021	0083A, 0091A, 0092A, 0093A,	
		October 6, 2021	0111A, 0112A, 0113A, 91308,	
		October 27, 2021	91311: June 17, 2022	
		January 12, 2022	0041A, 0042A, 91304:	



		· ·	-
	February 1, 2022	July 13, 2022	
	March 7, 2022	0124A, 0134A (18 years and older):	
	April 26, 2022	August 31, 2022	
	May 19, 2022	0134A (12 years	
	June 7, 2022	through 17 years), 0144A, 0154A, 91315:	
	July 6, 2022	October 12, 2022	
	August 31, 2022	0044A: October 19, 2022	
	October 10, 2022	0164A, 0173A,	
	November 16, 2022	91316, 91317: December 8, 2022	
	December 9, 2022		
	March 17, 2023	0174A: March 14, 2023	
	May 1, 2023	0121A, 0141A, 0142A, 0151A, 0171A, 0172A: April 18, 2023	
		0021A, 0022A, 0104A, 91302, 91310:	
		Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	
Medicine Immunization Administration for Vaccines/Toxoids	New and Revised Guidelines	New and Revised Guidelines Effective	New and Revised Guidelines
 ▶ Report vaccine immunization administration codes (90460, 90461, 90471-90474, 0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 	Released to AMA Website	0001A, 0002A,	Publication
0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A,	November 10, 2020	91300: December 11, 2020	CPT [®] 2022/2023/2024
0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A,	December 17, 2020	0011A, 0012A, 91301: December 18, 2020	3======================================
0173A, 0174A) in addition to the vaccine and toxoid code(s) (90476-90759, 91300-9131791316913159131191310,	January 19, 2021	,	
91301, 91302, 91303, 91304, <u>91305, 91306, 91307, 91308, 91309</u>).	March 1, 2021	0031A, 91303: February 27, 2021	
Report codes 90460 and 90461 only when the physician or other qualified health care professional provides face-to-face	May 4, 2021	0003A, 0013A: August 12, 2021	
counseling of the patient/family during the administration of	July 30, 2021	0004A: September	
a vaccine other than when performed for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccines. For	August 16, 2021	22, 2021	
immunization administration of any vaccine, other than	September 3, 2021		

4



SARS-CoV-2 (coronavirus disease [COVID-19]) vaccines,
that is not accompanied by face-to-face physician or other
qualified health care professional counseling to the
patient/family/guardian or for administration of vaccines to
patients over 18 years of age, report 90471-90474. (See
also Instructions for Use of the CPT Codebook for
definition of reporting qualifications.)◀

► Report 0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A for immunization administration of SARS-CoV-2 (coronavirus disease [COVID-19]) vaccines only. Each administration code is specific to each individual vaccine product (eg. 91300-91317913169131591311, 91310, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309), the dosage schedule (eg, first dose, second dose), and counseling, when performed. The appropriate administration code is chosen based on the type of vaccine and the specific dose number the patient receives in the schedule. For example, 0012A is reported for the second dose of vaccine 91301. Do not report 90460-90474 for the administration of SARS-CoV-2 (coronavirus disease [COVID-19]) vaccines. Codes related to SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine administration are listed in Appendix Q, with their associated vaccine code descriptors, vaccine administration codes, patient age, vaccine manufacturer, vaccine name(s), National Drug Code (NDC) Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code descriptor and must be the vaccine represented by the manufacturer and vaccine name listed in Appendix Q. ◀

If a significant separately identifiable Evaluation and Management service (eg, new or established patient office or other outpatient services [99202-99215], office or other outpatient consultations [99242-99245], emergency department services [99281-99285], preventive medicine services [99381-99429]) is performed, the appropriate E/M service code should be reported in addition to the vaccine and toxoid administration codes.

A component refers to all antigens in a vaccine that prevent disease(s) caused by one organism (90460 and 90461). Multi-valent antigens or multiple serotypes of antigens against a single organism are considered a single component of vaccines. Combination vaccines are those vaccines that contain multiple vaccine components. Conjugates or adjuvants contained in vaccines are not considered to be component parts of the vaccine as defined above.

(For allergy testing, see 95004 et seg)

(For skin testing of bacterial, viral, fungal extracts, see 86485-86580)

October 6, 2021	0034A, 0064A, 91306:
October 27, 2021	October 20, 2021
January 12, 2022 February 1, 2022 March 7, 2022	0051A, 0052A, 0053A, 0054A, 0071A, 0072A, 91305, 91307: October 29, 2021
April 26, 2022	2022
May 19, 2022	0094A, 91309: March 29, 2022
June 7, 2022 July 6, 2022	0074A: May 17, 2022
July 6, 2022 August 31, 2022 October 10, 2022 November 16, 2022 December 9, 2022 March 17, 2023 May 1, 2023	0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0111A, 0112A, 0113A, 91308, 91311: June 17, 2022 0041A, 0042A, 91304: July 13, 2022 0124A, 0134A (18 years and older): August 31, 2022 0134A (12 years through 17 years), 0144A, 0154A, 91315: October 12, 2022 0044A: October 19, 2022 0164A, 0173A, 91316, 91317: December 8, 2022 0174A: March 14, 2023
	0121A, 0141A, 0142A, 0151A, 0171A, 0172A: April 18, 2023
	0021A, 0022A,

0104A, 91302,

91310: Effective upon receiving



	•		3 ,	•
	(For therapeutic or diagnostic injections, see 96372-96379)		Emergency Use Authorization or approval from the Food and Drug Administration	
90460	Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered			
+ 90461	each additional vaccine or toxoid component administered (List separately in addition to code forprimary procedure) (Use 90460 for each vaccine administered. For vaccines	New Parenthetical Note Released to AMA Website	New and Revised Parenthetical Note Effective	New and Revised Parenthetical Note
	withmultiple components [combination vaccines], report 90460 inconjunction with 90461 for each additional	November 10, 2020	91300: December 11, 2020	Publication CPT®
	component in a given vaccine) ▶ (Do not report 90460, 90461 in conjunction with 91300-91317913169131591311, 91310, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309, unless both a severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine/toxoid product and at least one vaccine/toxoid product from 90476-90759 are administered at the same encounter) ◀	Revised Parenthetical Note Released to AMA Website December 17, 2020 January 19, 2021 March 1, 2021 May 4, 2021 September 3, 2021 October 6, 2021 February 1, 2022 March 7, 2022	91301: December 18, 2020 91303: February 27, 2021 91306: October 20, 2021 91305, 91307: October 29, 2021 91309: March 29, 2022 91308, 91311: June 17, 2022 91304: July 13, 2022 91315: October 12, 2022	2022/2023/2024
		April 26, 2022 May 19, 2022 August 31, 2022	91316, 91317: December 8, 2022 91302, 91310: Effective upon	
		November 16, 2022	receiving Emergency Use Authorization or	
		December 9, 2022	approval from the Food and Drug Administration	
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)			
	(Do not report 90471 in conjunction with 90473)			



+ 90472	each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) (Use 90472 in conjunction with 90460, 90471, 90473) ▶ (Do not report 90471, 90472 in conjunction with 91300-91317913169131591311913149, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309, unless both a severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine/toxoid product and at least one vaccine/toxoid product from 90476-90759 are administered at the same encounter) ◄ (For immune globulins, see 90281-90399. For administration of immune globulins, see 96365, 96366, 96367, 96368, 96369, 96370, 96371, 96374) (For intravesical administration of BCG vaccine, see 51720, 90586)	New Parenthetical Note Released to AMA Website November 10, 2020 Revised Parenthetical Note Released to AMA Website December 17, 2020 January 19, 2021 March 1, 2021 May 4, 2021 September 3, 2021 October 6, 2021 February 1, 2022 March 7, 2022 April 26, 2022 May 19, 2022 August 31, 2022 November 16, 2022 December 9, 2022	New and Revised Parenthetical Note Effective 91300: December 11, 2020 91301: December 18, 2020 91303: February 27, 2021 91306: October 20, 2021 91305, 91307: October 29, 2021 91309: March 29, 2022 91308, 91311: June 17, 2022 91304: July 13, 2022 91315: October 12, 2022 91316, 91317: December 8, 2022 91316, 91317: December 8, 2022 91302, 91310: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	New and Revised Parenthetical Note Publication CPT® 2022/2023/2024
90473	Immunization administration by intranasal or oral route; 1 vaccine (single or combination vaccine/toxoid) (Do not report 90473 in conjunction with 90471)		Administration	
+ 90474	each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure) (Use 90474 in conjunction with 90460, 90471, 90473) ▶ (Do not report 90473, 90474 in conjunction with 91300-9131791316913159131191310, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309, unless both a severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [coronavirus disease {COVID-19}] vaccine/toxoid	New Parenthetical Note Released to AMA Website November 10, 2020 Revised Parenthetical Note Released to AMA Website	New and Revised Parenthetical Note Effective 91300: December 11, 2020 91301: December 18, 2020 91303: February 27, 2021	New and Revised Parenthetical Note Publication CPT® 2022/2023/2024

CPT © Copyright 2023 American Medical Association.

All rights reserved. AMA and CPT are registered trademarks of the American Medical Association. Updated August 2, 2023



	product and at least one vaccine/toxoid product from 90476- 90759 are administered at the same encounter) ◀	December 17, 2020	91306: October 20, 2021	
		January 19, 2021 March 1, 2021	91305, 91307:	
		May 4, 2021	October 29, 2021	
		September 3, 2021	91309: March 29, 2022	
		October 6, 2021	91308, 91311: June 17, 2022	
		February 1, 2022	91304: July 13, 2022	
		March 7, 2022	91315: October 12,	
		April 26, 2022	2022	
		May 19, 2022	91316, 91317: December 8, 2022	
		August 31, 2022	91302, 91310:	
		November 16, 2022	Effective upon receiving	
		December 9, 2022	Emergency Use Authorization or approval from the Food and Drug Administration	
◆0001A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose	November 10, 2020	December 11, 2020 No longer authorized for use in the United States as of April 18, 2023	CPT [®] 2022
◆0002A	second dose	November 10, 2020	December 11, 2020 No longer authorized for use in the United States as of April 18, 2023	CPT [®] 2022
◆0003A	third dose	July 30, 2021	August 12, 2021 No longer authorized for use in the United States as of April 18,	CPT [®] 2023
◆ 0004A	booster dose	September 3, 2021	2023 0001A, 0002A,	CPT®
	► (Report 0001A, 0002A <u>, 0003A, 0004A</u> for the administration of vaccine 91300) ◀	October 6, 2021	91300: December 11, 2020	2022/2023/2024
		February 1, 2022		

8

Updated August 2, 2023



► (Do not report 0001A, 0002A, 0003A, 0004A in conjunction with 91305, 91307, 91308, 91312, 91315,	August 31, 2022	0003A: August 12, 2021	
<u>91317</u> , ¬	December 9, 2022	0004A: September- 22, 2021	
		91305, 91307: October 29, 2021	
		91308: June 17, 2022	
		91312: August 31, 2022	
		91315: October 12, 2022	
		91317: December 8, 2022	
Immunization administration by intramuscular injection of	September 3, 2021	October 29, 2021	CPT® 2023
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose		No longer authorized for use in the United States as of April 18, 2023	
second dose	September 3, 2021	October 29, 2021	CPT® 2023
		No longer authorized for use in the United States as of April 18, 2023	
third dose	September 3, 2021	October 29, 2021	CPT® 2023
		No longer authorized for use in the United States as of April 18, 2023	
booster dose	September 3, 2021	91300: December 11,	CPT®
► (Report 0051A, 0052A, 0053A, 0054A for the administration of vaccine 91305) ◀	February 1, 2022		2023/2024
► (Do not report 0051A, 0052A, 0053A, 0054A in conjunction with 91300, 91307, 91308, 91312, 91315, 91317) ◀	August 31, 2022 December 9, 2022	0053A, 0054A, 91305, 91307:	
<u> </u>	, , , , , , , , , , , , , , , , , , , 	91308: June 17, 2022	
		91312: August 31, 2022	
	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose second dose booster dose ▶ (Report 0051A, 0052A, 0053A, 0054A for the administration of vaccine 91305) ◀ ▶ (Do not report 0051A, 0052A, 0053A, 0054A in	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose September 3, 2021 third dose September 3, 2021 September 3, 2021 September 3, 2021 Entire dose September 3, 2021 September 3, 2021 September 3, 2021 February 1, 2022 August 31, 2022 August 31, 2022 August 31, 2022	August 31, 2022 December 9, 2022 Plank September 32, 2021 Plank September 17, 2022 Plank September 18, 2022 Plank September 18, 2022 Plank September 18, 2022 Plank September 19, 2023 Plank September 19, 2023 Plank September 19, 2024 Plank September 19, 2024 Plank September 19, 2024 Plank September 19, 2024 Plank September 19, 2025 Plank September 19, 2025



	moorporation of Non Abbre		C ,	-
			91315: October 12, 2022	
			91317: December 8, 2022	
			Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023	
# ● 0121A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; single dose	May 1, 2023	April 18, 2023	CPT [®] 2024
# <u>▲</u> •0124A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3-mL dosage, tris-sucrose formulation, booster-additional dose ▶ (Report 0121A, 0124A for the administration of vaccine 91312) ◀ ▶ (Do not report 0121A, 0124A in conjunction with 91300, 91305, 91307, 91308, 91315, 91317) ◀	August 31, 2022 December 9,2022 Revised Code Released to AMA Website: May 1, 2023 Revised Parenthetical Note Released to AMA Website May 1, 2023	91300: December 11, 2020 91305, 91307: October 29, 2021 91308: June 17, 2022 0124A, 91312: August 31, 2022 91315: October 12, 2022 91317: December 8, 2022 0121A: April 18, 2023 Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023 Revised Code Effective:	CPT® 2024
# ● 0071A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	October 6, 2021	April 18, 2023 October 29, 2021 No longer authorized for use in the United States as of April 18, 2023	CPT [®] 2023



		<u> </u>		
# ● 0072A	second dose	October 6, 2021	October 29, 2021 No longer authorized for use in the United States as of April 18, 2023	CPT [®] 2023
# ● 0073A	third dose	January 12, 2022	January 3, 2022 No longer authorized for use in the United States as of April 18, 2023	CPT [®] 2023
# ● 0074A	booster dose ► (Report 0071A, 0072A, 0073A, 0074A for the administration of vaccine 91307) ► (Do not report 0071A, 0072A, 0073A, 0074A in conjunction with 91300, 91305, 91308, 91312, 91315, 91317) ■	April 26, 2022 August 31, 2022 December 9, 2022	91300: December 11, 2020 0071A, 0072A, 91305: October 29, 2021 0073A: January 3, 2022 0074A: May 17, 2022 91308: June 17, 2022 91315: October 12, 2022 91317: December 8, 2022 Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023	CPT® 2023/2024
#●0151A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose	May 1, 2023	April 18, 2023	CPT [®] 2024
# <u>▲</u> •0154A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2-	August 31, 2022 December 9, 2022	91300: December 11, 2020 91305, 91307:	CPT [®] 2024



mL dosage, diluent reconstituted, tris-sucrose formulation, booster additional dose ► (Report 0151A, 0154A for the administration of vaccine 91315) ◄	Revised Code Released to AMA Website: May 1, 2023	October 29, 2021 91308: June 17, 2022 91312:	
► (Do not report <u>0151A</u> , 0154A in conjunction with 91300, 91305, 91307, 91308, 91312, <u>91317</u>) ◀	Revised Parenthetical Note Released to AMA Website May 1, 2023	August 31, 2022 0154A, 91315: October 12, 2022 91317: December 8, 2022	
		O151A: April 18, 2023 Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023	
		Revised Code Effective: April 18, 2023	
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	February 1, 2022	June 17, 2022 No longer authorized for use in the United States as of April 18, 2023	CPT [®] 2023
0082A second dose	February 1, 2022	June 17, 2022 No longer authorized for use in the United States as of April 18, 2023	CPT [®] 2023
third dose ► (Report 0081A, 0082A, 0083A) for the administration of vaccine 91308) ► (Do not report 0081A, 0082A, 0083A) in conjunction with 91300, 91305, 91307, 91312, 91315, 91317) ■	June 7, 2022 August 31, 2022 December 9, 2022	91300: December 11, 2020 91305, 91307: October 29, 2021 0081A, 0082A, 0083A, 91308: June 17, 2022 91312: August 31, 2022 91315: October 12,	CPT® 2023/2024
	<u> </u>	<u> </u>	9081A, 0082A, 0083A, 91308: June 17, 2022 91312: August 31,



			91317: December 8, 2022 Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023	
# ● 0171A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	May 1, 2023	April 18, 2023	CPT [®] 2024
#●0172A	second dose	May 1, 2023	April 18, 2023	CPT® 2024
# <u>▲</u> •0173A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL-desage, diluent reconstituted, tris-sucrose formulation,₁ third dose (Report 0173A for the administration of vaccine 91317) ►(Use 0173A in conjunction with 91317 only when used as a third dose administration of primary series for 91308, [ie, following administration of 0081A, 0082A]) ►(Do not report 0173A in conjunction with 91300, 91305, 91307, 91308, 91312, 91315) ■	Revised Code Released to AMA Website: March 17, 2023 May 1, 2023 Revised Parenthetical Note Released to AMA Website March 17, 2023	91300: December 11, 2020 91305, 91307: October 29, 2021 0081A, 0082A, 91308: June 17, 2022 91312: August 31, 2022 91315: October 12, 2022 0173A, 91317: December 8, 2022 Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023 Revised Code Effective: March 14, 2023 April 18, 2023	CPT® 2024
# <u>▲</u> •0174A	booster <u>additional</u> dose	March 17, 2023	91300: December 11, 2020	CPT® 2024



	► (Report <u>0171A, 0172A,</u> 0173A, 0174A for the administration of vaccine 91317) ◀	Revised Code Released to AMA Website:	91305, 91307: October 29, 2021	
	► (Use 0174A in conjunction with 91317 when used as an additional dose administration of primary series for 91308, [ie, following administration of 0081A, 0082A, 0083A]) ◀	May 1, 2023 Revised	0081A, 0082A, 0083A, 91308: June 17, 2022	
	► (Do not report <u>0171A, 0172A, 0173A, 0174A</u> in conjunction with 91300, 91305, 91307, 91308, 91312, 91315) ◀	Parenthetical Note Released to AMA Website	91312: August 31, 2022	
	91313)	May 1, 2023	91315: October 12, 2022	
			0173A, 91317: December 8, 2022	
			0174A: March 14, 2023	
			0171A, 0172A: April 18, 2023	
			Revised Code Effective:	
			April 18, 2023	
⊕ 0011A	Immunization administration by intramuscular injection of severeacute respiratory syndrome coronavirus 2 (SARS-	November 10, 2020	December 18, 2020	CPT® 2022
	CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; first dose		No longer authorized for use in the United States as of April 18, 2023	
● 0012A	second dose	November 10, 2020	December 18, 2020	CPT® 2022
			No longer authorized for use in the United States as of April 18, 2023	
◆ 0013A	third dose ►(Report 0011A, 0012A, 0013A for the administration of	August 16, 2021 New Parenthetical	0011A, 0012A, 91301: December 18, 2020	CPT [®] 2023/2024
	vaccine 91301) ◀ ►(Do not report 0011A, 0012A, 0013A in conjunction with 91306, 91309, 91311, 91313, 91314, 91316) ◀	Note Released to AMA Website	0013A: August 12, 2021	
	01000, 01000 <u>, 01011, 01010, 01011, 01010</u> , 1	March 7, 2022 Revised	91306: October 20, 2021	
		Parenthetical Note Released to AMA Website	91309: March 29, 2022	
		May 19, 2022	91311: June 17, 2022	
		August 31, 2022	91313 (18 years and older): August 31, 2022	
		November 16, 2022	01, 2022	



	moorporation of Alone Aloone		0 ,	•
			91313 (12 years through 17 years), 91314: October 12, 2022 91316: December 8, 2022 Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023	
# ◆ 0064A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose ▶ (Report 0064A for the administration of vaccine 91306) ◀ ▶ (Do not report 0064A in conjunction with 91301, 91309, 91311, 91313, 91314, 91316) ◀	September 3, 2021 New Parenthetical Note Released to AMA Website March 7, 2022 Revised Parenthetical Note Released to AMA Website May 19, 2022 August 31, 2022 November 16, 2022	91301: December 18, 2020 0064A, 91306: October 20, 2021 91309: March 29, 2022 91311: June 17, 2022 91313 (18 years and older): August 31, 2022 91313 (12 years through 17 years), 91314: October 12, 2022 91316: December 8, 2022 Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023	CPT® 2023/2024
# <u>▲</u> •0134A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, booster_additional_dose ▶ (Report 0134A for the administration of vaccine 91313) ◀ ▶ (Do not report 0134A in conjunction with 91301, 91306, 91309, 91311, 91314, 91316) ◀	August 31, 2022 November 16, 2022 Revised Code Released to AMA Website: May 1, 2023	91301: December 18, 2020 91306: October 20, 2021 91309: March 29, 2022 91311: June 17, 2022	CPT [®] 2024



			0134A and 91313 (18 years and older): August 31, 2022 0134A and 91313 (12 years through 17 years), 91314: October 12, 2022 91316: December 8, 2022 Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023 Revised Code Effective: April 18, 2023	
# ● 0141A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; first dose	May 1, 2023	April 18, 2023	CPT [®] 2024
#●0142A	second dose	May 1, 2023	April 18, 2023	CPT® 2024
# <u>▲</u> •0144A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CeV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, booster additional dose ▶ (Report 0141A, 0142A, 0144A for the administration of vaccine 91314) ◀ ▶ (Do not report 0141A, 0142A, 0144A in conjunction with 91301, 91306, 91309, 91311, 91313, 91316) ◀	August 31, 2022 November 16, 2022 Revised Code Released to AMA Website: May 1, 2023 Revised Parenthetical Note Released to AMA Website May 1, 2023	91301: December 18, 2020 91306: October 20, 2021 91309: March 29, 2022 91311: June 17, 2022 0144A, 91313 (12 years through 17 years), 91314: October 12, 2022 91316: December 8, 2022 0141A 0142A: April 18, 2023 Highlighted and stricken codes in the	CPT® 2024



			no longer authorized for use in the United States as of April 18, 2023 Revised Code Effective: April 18, 2023	
# • 0091A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; first dose, when administered to individuals 6 through 11 years	July 6, 2022	June 17, 2022 No longer authorized for use in the United States as of April 18, 2023	CPT [®] 2024
# • 0092A	second dose, when administered to individuals 6 through 11 years	July 6, 2022	June 17, 2022 No longer authorized for use in the United States as of April 18, 2023	CPT [®] 2024
#●0093A	third dose, when administered to individuals 6 through 11 years	July 6, 2022	June 17, 2022 No longer authorized for use in the United States as of April 18, 2023	CPT [®] 2024
# <u>▲</u> ◆0094A	Immunization administration by intramuscular- injection of severe acute respiratory syndrome- corenavirus 2 (SARS CoV-2) (corenavirus- disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL desage booster dose, when administered to individuals 18 years and older ▶ (Report 0091A, 0092A, 0093A, 0094A for the administration of vaccine 91309) ◀ ▶ (Do not report 0091A, 0092A, 0093A, 0094A in conjunction with 91301, 91306, 91311, 91313, 91314, 91316) ◀	New Code Released to AMA Website: March 7, 2022 Revised Parenthetical Note Released to AMA Website May 19, 2022 July 6, 2022 August 31, 2022 November 16, 2022 Revised Code Released to AMA Website: July 6, 2022	91301: December 18, 2020 91306: October 20, 2021 91309: March 29, 2022 New Code Effective: 0094A: March 29, 2022 0091A, 0092A, 0093A, 91311: June 17, 2022 Revised Code Effective: 0094A: July 6, 2022 91313 (18 years and older): August 31, 2022 91313 (12 years through 17 years), 91314: October 12,	CPT® 2023/2024



			91316: December 8, 2022 Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023	
◆0021A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 ¹⁰ viral particles/0.5 mL dosage; first dose	December 17, 2020	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2022
◆0022A	second dose ► (Report 0021A, 0022A for the administration of vaccine 91302) ◀	December 17, 2020	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2022
<u>▲</u> •0031A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5 mL dosage; single dose	New Code Released to AMA Website: January 19, 2021 Revised Code Released to AMA Website: October 27, 2021	New Code Effective: February 27, 2021 Revised Code Effective: October 20, 2021 No longer authorized for use in the United States as of June 1, 2023	CPT [®] 2022/2023
◆0034A	booster dose ►(Report 0031A, 0034A for the administration of vaccine 91303) ◄	October 27, 2021	0031A, 91303: February 27, 2021 0034A: October 20, 2021 No longer authorized for use in the United States as of June 1, 2023	CPT [®] 2023
● 0041A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage; first dose	May 4, 2021	July 13, 2022	CPT [®] 2022



● 0042A	second dose	May 4, 2021	July 13, 2022	CPT® 2022
●0044A	booster dose ► (Report 0041A, 0042A, 0044A for the administration of vaccine 91304) ◀	October 10, 2022	October 19, 2022	CPT [®] 2024
◆ 0104A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, booster dose ▶(Report 0104A for the administration of vaccine 91310) ◄	April 26, 2022	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2023
◆ 0111A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose	May 19, 2022	June 17, 2022 No longer authorized for use in the United States as of April 18, 2023	CPT [®] 2023
◆ 0112A	second dose	May 19, 2022	June 17, 2022 No longer authorized for use in the United States as of April 18, 2023	CPT [®] 2023
●0113A	third dose ► (Report 0111A, 0112A, <u>0113A</u> for the administration of vaccine 91311) ► (Do not report 0111A, 0112A, <u>0113A</u> in conjunction with 91301, 91306, 91309, <u>91313</u> , <u>91314</u> , <u>91316</u>) ■	July 6, 2022 August 31, 2022 November 16, 2022	91301: December 18, 2020 91306: October 20, 2021 91309: March 29, 2022 0111A, 0112A, 0113A, 91311: June 17, 2022 91313 (18 years and older): August 31, 2022 91313 (12 years through 17 years), 91314: October 12, 2022 91316: December 8, 2022 Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18,	CPT® 2023/2024



			<i>O</i> , <i>O</i>	•
▲• 0164A	Immunization administration by intramuscular injection of	November 16, 2022	91301: December 18,	CPT [®] 2024
	severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, booster_additional_dose ▶ (Report 0164A for the administration of vaccine 91316) ◀ ▶ (Do not report 0164A in conjunction with 91301, 91306, 91309, 91311, 91313, 91314) ◀	Revised Code Released to AMA Website: May 1, 2023	2020 91306: October 20, 2021 91309: March 29, 2022 91311: June 17, 2022 91313 (18 years and older): August 31, 2022 91313 (12 years through 17 years), 91314: October 12, 2022 0164A, 91316: December 8, 2022 Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023 Revised Code Effective: April 18, 2023 May 1, 2023	
	Vaccines, Toxoids			
	To assist users to report the most recent new or revised vaccine product codes, the American Medical Association (AMA) currently uses the CPT website, which features updates of CPT Editorial Panel actions regarding these products. Once approved by the CPT Editorial Panel, these codes will be made available for release on a semiannual (twice a year: July 1 and January 1) basis. As part of the electronic distribution, there is a six-month implementation period from the initial release date (ie, codes released on January 1 are eligible for use on July 1 and codes released on July 1 are eligible for use January 1).			



The CPT Editorial Panel, in recognition of the public health interest in vaccine products, has chosen to publish new vaccine product codes prior to approval by the US Food and Drug Administration (FDA). These codes are indicated with the w symbol and will be tracked by the AMM to monitor FDA approval status. Once the FDA status changes to approval, the w symbol will be removed. CPT users should refer to the AMA CPT website (www.ama-assn.org/do/cpt-vaccine) for the most up-to-date information on codes with the w symbol. ▶ Codes 90476-90759, 91300-91317913169131591311 (1913-91306, 91302, 91303, 91309, 91				
1319, 91301, 91302, 91303, 91304_91305, 91306, 91307_91308, 91308, 91308 elaesed to AMA website Coronavirus disease [COVID-19]), the vaccine/toxoid product codes (90476-90759) must be used in addition to an immunization administration code(s) (90460, 90461, 90471, 90472, 90473, 90474). To report the administration of a SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine, the vaccine/toxoid product codes (91300-9131791316913913191319, 91301, 91302, 91304, 91305, 91306, 91307, 91308, 91309, 91301, 91305, 91306, 91307, 91308, 91309, 91301, 90214, 00224, 00314, 00324, 00344, 00314, 00344, 00424, 00724, 00734, 00724, 00734, 00744, 00814, 00844, 00114, 01124, 01134, 01244, 01344, 011414, 01124, 01134, 01544, 01644, 01714, 01724, 01734, 017	interest in vaccine products, has chosen to publish new vaccine product codes prior to approval by the US Food and Drug Administration (FDA). These codes are indicated with the *\mathbb{\sigma}\$ symbol and will be tracked by the AMA to monitor FDA approval status. Once the FDA status changes to approval, the *\mathbb{\sigma}\$ symbol will be removed. CPT users should refer to the AMA CPT website (www.ama-assn.org/go/cpt-vaccine) for the most up-to-date information on codes with			
the administration of a vaccine/toxoid other than SARS-CoV-2 (coronavirus disease [COVID-19]), the vaccine/toxoid product codes (90476-90759) must be used in addition to an immunization administration code(s) (90460, 90461, 90471, 90472, 90473, 90474). To report the administration of a SARS-CoV-2 (coronavirus disease) (COVID-19]) vaccine, the vaccine/toxoid product codes (91300-9131791316913159131191310, 91301, 91302, 91303, 91304, 91306, 91306, 91306, 91307, 91308, 91309) should be reported with the corresponding immunization administration codes (0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0012A, 011A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0	<u>91310, 91301, 91302, 91303, 91304, 91305, 91306, 91307, </u>	Guidelines	Guidelines	Revised
2 (coronavirus disease [COVID-19]), the vaccine/toxoid product codes (90476-90759) must be used in addition to an immunization administration code(s) (90460, 90461, 90471, 90472, 90473, 90474). To report the administration of a SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine, the vaccine/toxoid product codes (91300-9131791316913159131191310, 91301, 91302, 91303, 91304, 91306, 91306, 91307, 91308, 91309) should be reported with the corresponding immunization administration codes (0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A). All SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine codes in this section are listed in Appendix Q with their associated vaccine code descriptors, vaccine administration codes, patient age, vaccine manufacturer, vaccine name(s), NDC Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code 2020 December 17, 2020 December 17, 2020 Danuary 19, 2021 March 1, 2021 May 4, 2021 December 17, 2020 March 1, 2021 May 4, 2021 December 17, 2020 March 1, 2021 May 4, 2021 December 18, 2020 March 1, 2021 May 4, 2021 December 17, 2020 Danuary 19, 2021 May 4, 2021 December 18, 2020 March 1, 2021 Do31A, 91303: February 27, 2021 South Andreha, 1, 2021 Do31A, 91303: February 27, 2021 Do31A, 91303: February			Effective	
product codes (90476-90759) must be used in addition to an immunization administration code(s) (90460, 90461, 90471, 90472, 90473, 90474). To report the administration of a SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine, the vaccine/toxoid product codes (91300-9131791316913159131191310, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309) should be reported with the corresponding immunization administration codes (0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0112A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A). All SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine codes in this section are listed in Appendix Q with their associated vaccine code descriptors, vaccine administration codes, patient age, vaccine manufacturer, vaccine name(s), NDC Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code		Website	00014 00024	Fublication
immunization administration code(s) (90460, 90461, 90471, 90472, 90473, 90474). To report the administration of a SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine, the vaccine/toxoid product codes (91300-9131791316913159131191310, 91301, 91302, 91303, 91304, 91306, 91306, 91307, 91308, 91309) should be reported with the corresponding immunization administration codes (0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0014A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0104A, 0111A, 0112A, 0113A, 0112A, 0114A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A). All SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine codes in this section are listed in Appendix Q with their associated vaccine code descriptors, vaccine administration codes, patient age, vaccine manufacturer, vaccine name(s), NDC Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code		November 10.	,,	CPT®
SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine, the vaccine/toxoid product codes (91300-9131791316913159131191310, 91302, 91303, 91303, 91304, 91306, 91306, 91307, 91308, 91309) should be reported with the corresponding immunization administration codes (0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0104A, 0111A, 0112A, 0113A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A). All SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine codes in this section are listed in Appendix Q with their associated vaccine code descriptors, vaccine administration codes, patient age, vaccine manufacturer, vaccine name(s), NDC Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code			December 11, 2020	2022/2023/2024
vaccine/toxoid product codes (91300- 9131791316913159131191310, 91301, 91302, 91303, 91304, 91306, 91306, 91307, 91308, 91309) should be reported with the corresponding immunization administration codes (0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A). All SARS- CoV-2 (coronavirus disease [COVID-19]) vaccine codes in this section are listed in Appendix Q with their associated vaccine code descriptors, vaccine administration codes, patient age, vaccine manufacturer, vaccine name(s), NDC Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code				
9131794316943159431194340, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309) should be reported with the corresponding immunization administration codes (0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 001AA, 002A, 002A, 0031A, 003AA, 004AA, 0042A, 001AA, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 012A, 012A, 013AA, 0141A, 0142A, 014A, 0151A, 015AA, 016AA, 0171A, 0172A, 0173A, 0174A). All SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine codes in this section are listed in Appendix Q with their associated vaccine code descriptors, vaccine administration codes, patient age, vaccine manufacturer, vaccine name(s), NDC Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code December 18, 2020 0031A, 91303: February 27, 2021 0031A, 91303: February 27, 2021 0031A, 91303: February 27, 2021 0034A, 0034A, 0013A: August 12, 2021 0004A: September 22, 2021 0034A, 0064A, 91304: August 12, 2021 0004A: September 3, 2021 0034A, 0064A, 91306: October 20, 2021 0051A, 0052A,				
91304, 91306, 91306, 91307, 91308, 91309) should be reported with the corresponding immunization administration codes (0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A). All SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine codes in this section are listed in Appendix Q with their associated vaccine code descriptors, vaccine administration codes, patient age, vaccine manufacturer, vaccine name(s), NDC Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code January 19, 2021 March 1, 2021 May 4, 2021 May 4, 2021 July 30, 2021 August 16, 2021 September 3, 2021 0034A, 0064A, 91303: February 27, 2021 0003A, 0013A: August 12, 2021 0004A: September 22, 2021 Cotober 3, 2021 October 6, 2021		2020		
reported with the corresponding immunization administration codes (0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A). All SARS-COV-2 (coronavirus disease [COVID-19]) vaccine codes in this section are listed in Appendix Q with their associated vaccine code descriptors, vaccine administration codes, patient age, vaccine manufacturer, vaccine name(s), NDC Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code March 1, 2021 May 4, 2021 May 4, 2021 July 30, 2021 4 U003A, 0013A; August 16, 2021 September 3, 2021 0034A, 0064A, 91303: February 27, 2021 May 4, 2021 0003A, 0013A; August 16, 2021 September 3, 2021 0034A, 0064A, 91303: February 27, 2021 0003A, 0013A; August 12, 2021 0004A: September 22, 2021 0034A, 0064A, 91303: February 27, 2021 0003A, 0013A; August 12, 2021 0004A: September 22, 2021 0034A, 0064A, 91303: February 27, 2021		January 19, 2021	2000111201 10, 2020	
0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A). All SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine codes in this section are listed in Appendix Q with their associated vaccine code descriptors, vaccine administration codes, patient age, vaccine manufacturer, vaccine name(s), NDC Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code August 16, 2021 0004A: September 0004A: September 0004A: September 0004A: September 0004A; O004A, 0004A, 0004A			0031A, 91303:	
0044A, 0051A, 0052A, 0053A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A). All SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine codes in this section are listed in Appendix Q with their associated vaccine code descriptors, vaccine administration codes, patient age, vaccine manufacturer, vaccine name(s), NDC Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code May 4, 2021 9003A, 0013A: August 12, 2021 0004A: September August 16, 2021 September 3, 2021 0034A, 0064A, 91306: October 6, 2021 October 6, 2021		March 1, 2021	February 27, 2021	
O072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A). All SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine codes in this section are listed in Appendix Q with their associated vaccine code descriptors, vaccine administration codes, patient age, vaccine manufacturer, vaccine name(s), NDC Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code August 12, 2021 O004A: September 2, 22, 2021 September 3, 2021 October 3, 2021 October 6, 2021 October 6, 2021		May 4, 2024	00034 00134	
0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A). All SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine codes in this section are listed in Appendix Q with their associated vaccine code descriptors, vaccine administration codes, patient age, vaccine manufacturer, vaccine name(s), NDC Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code July 30, 2021 O004A: September 2, 22, 2021 September 3, 2021 October 3, 2021 October 6, 2021 October 6, 2021		May 4, 2021	*	
0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A). All SARS-CoV-2 (coronavirus disease [COVID-19]) vaccine codes in this section are listed in Appendix Q with their associated vaccine code descriptors, vaccine administration codes, patient age, vaccine manufacturer, vaccine name(s), NDC Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code August 16, 2021 September 2, 0034A, 0064A, 91306: October 3, 2021 October 6, 2021 October 6, 2021		July 30, 2021	7 tagast 12, 2021	
CoV-2 (coronavirus disease [COVID-19]) vaccine codes in this section are listed in Appendix Q with their associated vaccine code descriptors, vaccine administration codes, patient age, vaccine manufacturer, vaccine name(s), NDC Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code September 3, 2021 October 3, 91306: October 20, 2021 October 6, 2021	0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A,	, ,		
this section are listed in Appendix Q with their associated vaccine code descriptors, vaccine administration codes, patient age, vaccine manufacturer, vaccine name(s), NDC Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code September 3, 2021 Cottober 3, 91306: October 6, 2021 October 6, 2021		August 16, 2021	22, 2021	
vaccine code descriptors, vaccine administration codes, patient age, vaccine manufacturer, vaccine name(s), NDC Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code 2021 October 20, 2021 October 6, 2021 0051A, 0052A,		Cantanahau 2	00344 00644	
patient age, vaccine manufacturer, vaccine name(s), NDC Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code October 20, 2021 October 6, 2021 October 6, 2021				
Labeler Product ID, and interval between doses. In order to report these codes, the vaccine must fulfill the code October 6, 2021 0051A, 0052A,		2021		
, , ,		October 6, 2021	,	
descriptor and must be the vaccine represented by the Cotober 27, 2021 Cot				
, , , , , , , , , , , , , , , , , , , ,	descriptor and must be the vaccine represented by the	October 27, 2021	0053A, 0054A,	
manufacturer and vaccine name listed in Appendix Q. ◀ January 12, 2022 9071A, 0072A, 91305, 91307:	manufacturer and vaccine name listed in Appendix Q. ◀	January 12, 2022		
► Do not report 90476-90759 in conjunction with the SARS-		January 12, 2022	· · · · · · · · · · · · · · · · · · ·	
CoV-2 (coronavirus disease [COVID-19]) immunization	CoV-2 (coronavirus disease [COVID-19]) immunization	February 1, 2022		
administration codes 0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 002A, 002A, 003A, 004A, 00			_	
0012A, 0013A, 0021A, 0022A, 0031A, 0041A, 0041A, 0042A, 0041A, 0052A, 0053A, 0054A, 0064A, 0064A,		March 7, 2022	2022	
0071A, 0072A, 0073A, 0082A, 0082A, 0083A, April 26, 2022		April 26, 2022	00044 01300	
0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, March 29, 2022		April 20, 2022		
0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, May 19, 2022		May 19, 2022		
U151A, U154A, U164A, U171A, U172A, U173A, U174A, Unloce both a SARS CoV 2 (corpopyirus disease ICOVID		-	0074A: May 17, 2022	
101) veccine/toxeid product and at least one veccine/toxeid		June 7, 2022	00044 00004	
product from 90476-90759 are administered at the same July 6, 2022 0081A, 0082A, 0091A, 0083A, 0091A,		July 6, 2022		
encounter. ◀ 5diy 0, 2022 60037, 00377, 0092A, 0093A,	encounter. ◀	July 0, 2022		
► Modifier 51 should not be reported with vaccine/toxoid August 31, 2022 → Modifier 51 should not be reported with vaccine/toxoid	► Modifier 51 should not be reported with vaccine/toxoid	August 31, 2022	, ,	
codes 90476-90759, 91300 <u>-9131791316913159131191310,</u>				
91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, October 10, 2022		October 10, 2022		
91309 when reported in conjunction with administration codes 90460, 90461, 90471, 90472, 90473, 90474, 0001A. November 16, 2022		November 16, 2022	June 17, 2022	
codes 90460, 90461, 90471, 90472, 90473, 90474, 0001A, November 16, 2022 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A,		14040111061 10, 2022		



O022A, 0031A, 0034A, 0041A, 0042A, 0051A, 0052A, 0053A, 00				-
If a significantly separately identifiable Evaluation and Management (EM) service (e.g., office or other outpatient services, preventive medicine services is performed, the appropriate EM sorvice code should be reported in addition to the vaccine and toxoid administration codes. To meet the reporting requirements of immunization registries, vaccine distribution programs, and reporting systems (e.g., vaccine Adverse Event Reporting System) the exact vaccine product administration codes. To meet the reporting requirements of immunization registries, vaccine distribution programs, and reporting systems (e.g., vaccine Adverse Event Reporting System) the exact vaccine product administration codes in the exact vaccine products of the same vaccine type (e.g., hepatitis A. High) or the vaccine product is available in the performance of the exact vaccine and the exact vaccine are product is available in the performance of the exact vaccine and the exact vaccine and the exact vaccine are product in addition. The "when administration. disagn, or route of administration." The "when administered to" age descriptions included in CPT vaccine codes are not intended to identify a product's licensed age indication. The term "preservative agents that are not present in a sufficient concentration for the purpose of preserving the final vaccine formulation. The absence of a designation regarding a preservative does not necessarily indicate the presenous for preservative agents that are not present in a sufficient concentration for the purpose of preserving the final vaccine formulation. The absence of a designation regarding a preservative does not necessarily indicate the presenous or absence or absence or preservative designation (PI) for the licensed age indication before administering vaccine to a patient.	0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A,	March 17, 2023	91304: July 13, 2022	
services, preventive medicine services) is performed, the appropriate EVM service code should be reported in addition to the vaccine and toxoid administration codes. To meet the reporting requirements of immunization registries, vaccine distribution programs, and reporting systems (e.g., Vaccine Adverse Event Reporting System) the Multiple codes for a particular vaccine are provided in the CPT codebook when the schedule (number of doses or timing) differs for two or more products of the same vaccine type (e.g., hepatitis A, thill) or the vaccine products available in more than one chemical formulation, dosage, or route of administration. The "when administered to" age descriptions included in CPT vaccine codes are not intended to identify a product's licensed age indication. The term "preservative address includes use for vaccines that contain no preservative and vaccines that contain no preservative and vaccines that contain no preservative and reporting the purpose of preservities in the vaccines day indicate the preservative agents that are not preserviting information (P) for the licensed age indication. The tensor or preservative in the vaccines and indicate the preservative administering vaccine to a patient. Service of the product of the product of preservative in the vaccine. Refer to the product of preservative in the vaccine of a patient.	0171A, 0172A, 0173A, 0174A. ◀ If a significantly separately identifiable Evaluation and	May 1, 2023	years and older):	
To meet the reporting requirements of immunization registries, vaccine distribution programs, and reporting systems (eg.) Vaccine Adverse Event Reporting System) the exact vaccine product administrated needs to be reported. Multiple codes for a particular vaccine are provided in the CPT codebook when the schedule (number of doses or timing) differs for two or more products of the same vaccine type (eg., hepatitis. A Hib) or the vaccine product is available in more than one chemical formulation, dosage, or route of administration. The "when administration administration or approval and in the United States as of April 18, 2023 The "when administered to" age descriptions included in CPT vaccine codes are not intended to identify a product"s included use for vaccines that contain no preservative and vaccines that contain no preservative and vaccines that contain trace amounts of preservative and vaccines that contain trace amounts of preservative adens that are not preserving the final vaccine formulation. The absence of a designation regarding a preservative does not necessarily indicate the preservace or absence of preservative in the vaccine. Refer to the product's preservative administering vaccine to a patient. The "when administered to" age descriptions included in CPT vaccine codes are not intended to identify a product's increased age indication. The term' preservative and vaccines that contain trace amounts of preservative agents that are not preserving the final vaccine formulation. The absence of a designation regarding a preservative does not necessarily indicate the preservace or absence of preservative in the vaccine. Refer to the product's prescribing information (PI) for the licensed age indication before administering vaccine to a patient.	services, preventive medicine services) is performed, the appropriate E/M service code should be reported in addition		through 17 years), 0144A, 0154A,	
Multiple codes for a particular vaccine are provided in the CPT codebook when the schedule (number of doses or timing) differs for two or more products of the same vaccine type (eg. hepatitis A, Hib) or the vaccine product is available in more than one chemical formulation, dosage, or route of administration. 1014A, March 14, 2023 10121A, 0141A 0142A, 0151A, 0172A, 0172A; April 18, 2023 10131B, 1014D, 1014A, 0172A, 0172A; April 18, 2023 10131B, 1014D, 1014B, 1014B, 1014B, 1014B, 1014B, 1014B, 1014B, 1015B, 1014B, 1014	registries, vaccine distribution programs, and reporting systems (eg, Vaccine Adverse Event Reporting System) the		October 12, 2022 0044A: October 19,	
type [eg., hepatitis A, Hib) or the vaccine product is available in more than one chemical formulation, dosage, or route of administration. December 8, 2022 0174A: March 14, 2023 0121A, 0141A 0142A, 0151A, 0171A, 0172A: April 18, 2023 Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023 O021A, 0022A, 0104A, 91302, 91310: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration The "when administered to" age descriptions included in CPT vaccine codes are not intended to identify a product's licensed age indication. The term 'preservative free' includes use for vaccines that contain trace amounts of preservative and vaccines that contain trace amounts of preservative does not necessarily indicate the presence or absence of preservative in the vaccine. Refer to the product's preservative does not necessarily indicate the presence or absence of preservative in the vaccine. Refer to the product's preservative does not necessarily indicate the preservative of preservative in the vaccine. Refer to the product's preservative does not necessarily indicate the presence or absence of preservative in the vaccine. Refer to the product's preservative does not necessarily indicate the presence or absence of preservative in the vaccine. Refer to the product's preservative does not necessarily indicate the presence or absence of preservative in the vaccine. Refer to the product's preservative does not necessarily indicate the presence or absence of preservative and vaccine. Refer to the product's prescribing information (PI) for the licensed age indication before administering vaccine to a patient.	Multiple codes for a particular vaccine are provided in the CPT codebook when the schedule (number of doses or		0164A, 0173A,	
The "when administered to" age descriptions included in CPT vaccine codes are not intended to identify a product's licensed age indication. The term "preservative and vaccines that contain trace amounts of preservative and vaccines that contain regarding a preservative des not necessarily indicate the presence or absence of preservative in the vaccine. Refer to the production (PI) for the licensed age indication. Perservation from the purpose of preserving the final vaccine for administering vaccine to a patient. O121A, 0141A 0142A, 0151A, 0171A, 0172A; April 18, 2023 Highlighted and stricken codes in the Effective Column are no longer authorized for use in the United States as of April 18, 2023 0021A, 0022A, 0104A, 91302, 91310: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration New and Revised Guidelines Released to AMA Website November 10, 2020 0021A, 0022A, 0104A, 91302, 91310: Effective Released to AMA Website November 10, 2020 0021A, 0022A, 0104A, 91302, 91310: Effective Released to AMA Website November 10, 2020 0021A, 0022A, 0104A, 91302, 91310: Effective Released to AMA Website November 10, 2020 0021A, 0022A, 0104A, 91302, 91310: Effective Released to AMA Website 0021A, 0022A,	type (eg, hepatitis A, Hib) or the vaccine product is available in more than one chemical formulation, dosage, or route of		December 8, 2022 0174A: March 14,	
stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023 0021A, 0022A, 0104A, 91302, 91310: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration The "when administered to" age descriptions included in CPT vaccine codes are not intended to identify a product's licensed age indication. The term "preservative free" includes use for vaccines that contain no preservative and vaccines that contain trace amounts of preservative agents that are not present in a sufficient concentration for the purpose of preserving the final vaccine formulation. The absence of a designation regarding a preservative does not necessarily indicate the presence or absence of preservative in the vaccine. Refer to the product's prescribing information (PI) for the licensed age indication before administering vaccine to a patient. Stricken codes in the Effective City and not not not political to states as of April 18, 2023 O021A, 0022A, 0104A, 91302, 91310: Effective Quantification or approval from the Food and Drug Administration			0121A, 0141A 0142A, 0151A, 0171A, 0172A:	
The "when administered to" age descriptions included in CPT vaccine codes are not intended to identify a product's licensed age indication. The term "preservative free" includes use for vaccines that contain no preservative and vaccines that contain trace amounts of preservative agents that are not present in a sufficient concentration for the purpose of preserving the final vaccine formulation. The absence of a designation regarding a preservative does not necessarily indicate the presence or absence of preservative in the vaccine. Refer to the product's prescribing information (PI) for the licensed age indication before administering vaccine to a patient. New and Revised Guidelines Released to AMA Website November 10, 2020 November 10, 2020 P1301: December 11, 2020 P1303: February 27, 2021 March 1, 2021 March 1, 2021 Namary 19, 2021			stricken codes in the Effective column are no longer authorized for use in the United States as of April 18,	
CPT vaccine codes are not intended to identify a product's licensed age indication. The term "preservative free" includes use for vaccines that contain no preservative and vaccines that contain trace amounts of preservative agents that are not present in a sufficient concentration for the purpose of preserving the final vaccine formulation. The absence of a designation regarding a preservative does not necessarily indicate the presence or absence of preservative in the vaccine. Refer to the product's prescribing information (PI) for the licensed age indication before administering vaccine to a patient. Guidelines Released to AMA Website November 10, 2020 Planuary 19, 2020 December 17, 2020 91303: February 27, January 19, 2021 March 1, 2021 March 1, 2021			0104A, 91302, 91310: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug	
vaccines that contain trace amounts of preservative agents that are not present in a sufficient concentration for the purpose of preserving the final vaccine formulation. The absence of a designation regarding a preservative does not necessarily indicate the presence or absence of preservative in the vaccine. Refer to the product's prescribing information (PI) for the licensed age indication before administering vaccine to a patient. November 10, 2020 91301: December 18, 2022 91303: February 27, January 19, 2021 March 1, 2021 March 1, 2021	CPT vaccine codes are not intended to identify a product's licensed age indication. The term "preservative free"	Guidelines Released to AMA	Guidelines Effective	Revised Guidelines
absence of a designation regarding a preservative does not necessarily indicate the presence or absence of preservative in the vaccine. Refer to the product's prescribing information (PI) for the licensed age indication before administering vaccine to a patient. December 17, 2020 91303: February 27, January 19, 2021 March 1, 2021 0003A, 0013A:	vaccines that contain trace amounts of preservative agents that are not present in a sufficient concentration for the	November 10,	2020	CPT®
vaccine to a patient. March 1, 2021 0003A, 0013A:	absence of a designation regarding a preservative does not necessarily indicate the presence or absence of preservative in the vaccine. Refer to the product's prescribing information		91303: February 27,	



Separate codes are available for combination vaccines (eg,
Hib-HepB, DTap-IPV/Hib). It is inappropriate to code each
component of a combination vaccine separately. If a specific
vaccine code is not available, the unlisted procedure code
should be reported, until a new code becomes available.

▶ The vaccine/toxoid abbreviations listed in codes 90476-90759, 91300-9131791316913159131191310, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309 reflect the most recent US vaccine abbreviation references used in the Advisory Committee on Immunization Practices (ACIP) recommendations at the time of CPT code set publication. Interim updates to vaccine code descriptors will be made following abbreviation approval by the ACIP on a timely basis via the AMA CPT website (ama-assn.org/cpt-cat-i-vaccine-codes). The accuracy of the ACIP vaccine abbreviation designations in the CPT code set does not affect the validity of the vaccine code and its reporting function.

For the purposes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccinations, codes 0003A, 0013A, 0053A, 0073A, and-0083A, 0093A, and-0113A, and 0173A represent the administration of a third dose in the primary series (eg, patient with immunocompromising condition or patient age 6 months through 4 years) when the initial immune response following a two-dose primary vaccine series is likely to be insufficient (eg, immunocompromised patient). In contrast, the booster or additional dose codes 0004A, 0034A, 0044A, 0054A, and-0064A, 0074A, 0094A, and 0104A, 0124A, 0134A, 0144A, and-0154A, and-0164A, and 0174A represent the administration of a dose of vaccine when the initial immune response to a primary vaccine series was sufficient, but has likely waned over time. ◀

(For immune globulins, see 90281-90399. For administration of immune globulins, see 96365-96375)

May 4, 2021	August 12, 2021
September 3, 2021	0004A: September 22, 2021
October 6, 2021	0034A , 0064A, 91306:
October 27, 2021	October 20, 2021
January 12, 2022	0053A, 0054A, 91305, 91307:
February 1, 2022	October 29, 2021
March 7, 2022	0073A: January 3, 2022
April 26, 2022	
May 19, 2022	0094A, 91309: March 29, 2022
June 7, 2022	0074A: May 17, 2022
July 6, 2022	0083A, 0093A,
August 31, 2022	0113A, 91308, 91311: June 17, 2022
October 10, 2022	91304: July 13, 2022
November 16, 2022	0124A, 0134A (18
December 9, 2022	years and older): August 31, 2022
March 17, 2023	0134A (12 years
May 1, 2023	through 17 years), 0144A, 0154A, 91315:
	October 12, 2022
	0044A: October 19, 2022
	0164A, 0173A, 91316, 91317: December 8, 2022
	0174A: March 14, 2023
	Highlighted and

stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023

> 0104A, 91302, 91310: Effective upon receiving Emergency Use Authorization or

August 12, 2021



	•	1		1
			approval from the Food and Drug Administration	
# ● 91300	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL	New Code Released to AMA Website:	0001A, 0002A, 91300: December 11, 2020	CPT® 2022/2023/2024
	dosage, diluent reconstituted, for intramuscular use ►(Report 91300 with administration codes 0001A, 0002A, 0003A, 0004A) ◄	November 10, 2020 July 30, 2021	0003A: August 12, 2021	
	► (Do not report 91300 in conjunction with administration codes 0051A, 0052A, 0053A, 0054A, 0071A, 0072A,	September 3, 2021	0004A: September 22, 2021	
	<u>0073A, 0074A, 0081A, 0082A, 0083A, 0121A, 0124A,</u> <u>0151A, 0154A, 0171A, 0172A, 0173A, 0174A</u>)◀	October 6, 2021	0051A, 0052A,	
		January 12, 2022	0053A, 0054A, 0071A, 0072A: October 29, 2021	
		February 1, 2022	·	
		April 26, 2022	0073A: January 3, 2022	
		June 7, 2022	0074А: May 17, 2022	
		August 31, 2022	0081A, 0082A, 0083A:	
		December 9, 2022	June 17, 2022	
		March 17, 2023	0124A: August 31, 2022	
		Revised Parenthetical Note Released to AMA Website	0154A: October 12, 2022	
		May 1, 2023	0173A: December 8, 2022	
			0174A: March 14, 2023	
			0121A, 0151A, 0171A, 0172A: April 18, 2023	
			Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023	
#₩●91305	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])	September 3, 2021	0001A, 0002A: December 11, 2020	CPT® 2023/2024
	vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	October 6, 2021 January 12, 2022	0003A: August 12, 2021	
	► (Report 91305 with administration codes 0051A, 0052A, 0053A, 0054A) ◀	February 1, 2022	2321	



December 91305 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, 0071A, 0072A, 0073A, 0074A, 0081A, 0002A, 0003A, 0004A, 0071A, 0072A, 0151A, 0154A, 0171A, 0172A, 0173A, 0174A)					
0073A, 0074A, 0081A, 0082A, 0083A, 0171A √ 0151A, 0154A, 0171A, 0172A, 0173A, 0173A, 0174A √ 0151A, 0154A, 0171A, 0172A, 0173A, 0173A, 0173A √ 0151A, 0154A, 0171A, 0172A, 0173A, 0173A √ 0151A, 0154A, 0174A, 0172A, 0173A, 0173A, 0173A √ 0151A, 0154A, 0174A, 0172A, 0173A, 0173A √ 0151A, 0154A, 0174A, 0172A, 0173A, 0174A √ 0151A, 0154A, 0174A, 0174A, 0174A √ 0151A, 0154A, 0174A, 0174A, 0174A √ 0151A, 0154A, 0174A,			April 26, 2022		
December 09, 2022 March 17, 2023 Revised Parenthetical Note Released to AMA Website May 1, 2023 ## ●91312 Severe acute respiratory syndrome coronavirus 2 (SARS- COV-2) (coronavirus disease [COVID-19]) vaccine, mRNA- LNP, bivalent spike protein, preservative free, 30 meggu 3 LNP, 12023 August 31, 2022 August 31, 2023 Lightighted and stricken codes in the Effective Column are no longer authorized for use in the United States as of April 18, 2023 Lightighted and stricken codes in the Effective Column are no longer authorized for use in the United States as of April 18, 2023 August 31, 2022 December 9, 2022 August 31, 2022 December 11, 2023 December 11		0073A, 0074A, 0081A, 0082A, 0083A, 0121A, 0124A,	June 7, 2022	, ,	
#.★●91312 Severe acute respiratory syndrome coronavirus 2 (SARS-LNP, bivalent spike protein, preservative free, 30 meg/J. No. 2002 March 17, 2022 #.★●91312 Protein, preservative free, 30 meg/J. No. 2003 May 1, 2023 #.★●91312 Protein, preservative free, 30 meg/J. No. 2004, 0051A, 0052A, 0053A, 0051A, 0071A, 0072A, 0073A, 0074A,			August 31, 2022	0071A, 0072A,	
Revised Parenthetical Note Released to AMA Website May 1, 2023 Revised Parenthetical Note Released to AMA Website May 1, 2023 May 1, 2023 00341.4, 0082.A., 0082.A., 0083.4. 00834.0151.4, 01524., 01724. O1724. April 18, 2023 Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023 ###●91312 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (CoVID-19)) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use Revised Parenthetical Note Released to AMA Website Report 91312 with administration codes 00114, 00724, 00734,			December 09, 2022	October 29, 2021	
## \$91312 Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use (Report 91312 with administration codes 00014, 00024, 00034, 000					
# ■ 91312 Severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 meg/0.3 mt dosage, tris-sucrose formulation, for intramuscular use (Report 91312 with administration codes 00014, 0002A, 0003A, 0004A, 0051A, 0003A, 0017A, 0072A, 0073A, 00			Parenthetical	0074A: May 17, 2022	
#.★●91312 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tifs-sucrose formulation, for intramuscular use (Do not report 91312 in conjunction with administration codes 0001A, 0002A, 0003A, 0054A, 0071A, 0072A, 0073A, 0074A, 0073A, 0074A, 0073A, 0074A, 0073A, 0074A, 0073A, 0074A, 0081A, 0082A, 0083A, 0151A, 0154A, 0171A, 0172A, 0173A, 0173A, 0173A, 0174A) (May 1, 2023) (Discovery first of the content of t					
## •91312 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use (Do not report 91312 with administration codes 0001A, 0002A, 0003A, 0054A, 0074A, 0074A, 0074A, 0073A, 0073A, 0074A, 0073A, 0073A, 0074A, 0073A, 0074A, 0073A, 0073A, 0074A, 0073A, 0073A, 0074A, 0073A, 0073A, 0074A, 0073A, 007			May 1, 2023		
##●91312 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use (Do not report 91312 with administration codes 0014, 00024, 00034, 00044, 00514, 00524, 00834, 00744, 00744, 00744, 00814, 00824, 00834, 001514, 01544, 01744, 01724, 01734, 01744) (CPT® 2024					
##•91312 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease (COVID-19)) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use (Report 91312 with administration codes 0001A, 0002A, 0003A, 0004A, 0051A, 0054A, 0054A, 0074A, 0081A, 0074A, 0081A, 0074A, 0081A, 0074A, 00174A) August 31, 2022 0001A, 0002A: December 9, 2022 0001A, 0002A: December 9, 2022 0003A: August 12, 2024 0003A: August 12, 2024 0004A: September 22, 2024 0004A: September 22, 2024 0005A, 0054A, 0074A, 0081A, 0054A, 0054A, 0054A, 0054A, 0074A, 0081A, 0084A, 0				•	
# → ● 91312 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use ► (Report 91312 with administration codes 00121A, 00124A) ◄ ► (Do not report 91312 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, 0051A, 0052A, 0053A, 0054A, 0071A, 0072A, 0073A, 0074A, 0081A, 0081A, 0082A, 0083A, 0151A, 0154A, 0171A, 0172A, 0173A, 0174A) ★ May 1, 2023 1 Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023 2 Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023 August 31, 2022 December 9, 2022 March 17, 2023 Revised Parenthetical Note Released to AMA Website May 1, 2023 May 1, 2023 August 31, 2022 December 9, 2022 March 17, 2023 Revised Parenthetical Note Released to AMA Website May 1, 2023 May 1, 2023				*	
##•91312 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use (Report 91312 with administration codes 0121A, 0124A) (Do not report 91312 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, 0051A, 0052A, 0053A, 0054A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0151A, 0154A, 0171A, 0172A, 0173A, 0174A) (May 1, 2023) (Name of the Effective column are no longer authorized for use in the United States as of April 18, 2023 August 31, 2022 (0001A, 0002A) (December 9, 2022 (0003A: August 12, 2021 (December 9, 2022 (0003A: August				-	
##•91312 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use (Report 91312 with administration codes 0121A, 0124A) (Do not report 91312 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, 0051A, 0052A, 0053A, 0054A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0151A, 0154A, 0171A, 0172A, 0173A, 0174A) (May 1, 2023) Stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023 August 31, 2022 (0001A, 0002A: December 11, 2020) December 9, 2022 (0003A: August 12, 2021) March 17, 2023 (0004A: September 22, 2021) Revised Parenthetical Note Released to AMA Website (0051A, 0052A, 0053A, 0054A, 0071A, 0072A; (0053A, 0054A, 0071A, 0072A; (0053A, 0054A, 0071A, 0072A; (0071A, 007				0171A, 0172A:	
CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use (Report 91312 with administration codes 0121A, 0124A) ■ (Do not report 91312 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, 0051A, 0052A, 0053A, 0054A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0151A, 0154A, 0171A, 0172A, 0173A, 0174A) ■ (Do not report 91312 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, 0051A, 0052A, 0053A, 0053A, 0054A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0151A, 0154A, 0171A, 0172A, 0173A, 0174A) ■ (Do not report 91312 in conjunction with administration codes 0001A, 0002A, 0003A, 0005A, 0053A, 0053A, 0054A, 0051A, 0071A, 0072A; (Do not report 91312 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, 0051A, 0052A, 0053A, 0054A, 0051A, 0071A, 0072A; (Do not report 91312 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, 0051A, 0052A, 0053A, 0054A, 0051A, 0071A, 0072A; (Do not report 91312 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, 0051A, 0052A, 0053A, 0054A, 0051A, 0071A, 0072A; (Do not report 91312 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, 0051A, 0052A, 0053A, 0054A, 0071A, 0072A; (Do not report 91312 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, 00051A, 00052A, 0053A, 0054A, 0054A, 0071A, 0072A; (Do not report 91312 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, 00051A, 00052A, 0053A, 0054A, 0054A, 0071A, 0072A; (Do not report 91312 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, 00051A, 00052A, 00053A, 00054A,				stricken codes in the Effective column are no longer authorized for use in the United States as of April 18,	
 ▶ (Report 91312 with administration codes 0121A, 0124A) ▶ (Do not report 91312 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, 0051A, 0052A, 0053A, 0054A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0151A, 0154A, 0171A, 0172A, 0173A, 0174A) ■ Revised Parenthetical Note Released to AMA Website ■ May 1, 2023 	# →91312	CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3	December 9, 2022	December 11, 2020 0003A: August 12,	CPT [®] 2024
Note Released to codes 0001A, 0002A, 0003A, 0004A, 0051A, 0052A, 0053A, 0054A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0151A, 0154A, 0171A, 0172A, 0173A, 0174A)			Revised	0004A: September-	
0054A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0151A, 0154A, 0171A, 0172A, 0173A, 0174A) ◀ May 1, 2023 Hay 1, 2023			Note Released to	·	
UCCODE 29, 2021		0054A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A,		0053A, 0054A,	
0073A: January 3, 2022					



			0074A: May 17, 2022	
			0081A, 0082A, 0083A: June 17, 2022	
			0124A, 91312: August 31, 2022	
			0154A: October 12, 2022	
			0173A: December 8, 2022	
			0174A: March 14, 2023	
			0121A, 0151A, 0171A, 0172A: April 18, 2023	
			Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023	
# // ●91307	Severe acute respiratory syndrome coronavirus 2 (SARS	October 6, 2021	0001A, 0002A:	CPT®
	CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2	January 12, 2022	December 11, 2020	2023/2024
	mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	February 1, 2022	0003A: August 12, 2021	
	►(Report 91307 with administration codes 0071A, 0072A, 0073A, 0074A)◀	April 26, 2022	0004A: September 22, 2021	
	► (Do not report 91307 in conjunction with administration	June 7, 2022	0051A, 0052A,	
	codes 0001A, 0002A, 0003A, 0004A, 0051A, 0052A, 0053A, 0054A, 0081A, 0082A, 0083A, 0121A, 0124A, 0151A,	August 31, 2022	0053A, 0054A, 0071A, 0072A,	
	<u>0154A, 0171A, 0172A, 0173A, 0174A</u>) ◀	December 9, 2022	91307:	
		March 17, 2023	October 29, 2021	
		Revised	0073A: January 3, 2022	
		Parenthetical Note Released to	0074A: May 17, 2022	
		AMA Website	0081A, 0082A,	
		May 1, 2023	0083A: June 17, 2022	
			0124A: August 31, 2022	
			0154A: October 12, 2022	



		1		
			0173A: December 8, 2022 0174A: March 14, 2023 0121A, 0151A, 0171A, 0172A: April 18, 2023 Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023	
# . ₩•91315	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use ▶ (Report 91315 with administration codes 0151A, 0154A) ◀ ▶ (Do not report 91315 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, 0051A, 0052A, 0053A, 0054A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0121A, 0124A, 0171A, 0172A, 0173A, 0174A) ◀	August 31, 2022 December 9, 2022 March 17, 2023 Revised Parenthetical Note Released to AMA Website May 1, 2023	0001A, 0002A: December 11, 2020 0003A: August 12, 2021 0004A: September 22, 2021 0051A, 0052A, 0053A, 0054A, 0071A, 0072A: October 29, 2021 0073A: January 3, 2022 0074A: May 17, 2022 0081A, 0082A, 0083A: June 17, 2022 0124A: August 31, 2022 0154A, 91315: October 12, 2022 0173A: December 8, 2022 0174A: March 14, 2023 0121A, 0151A, 0171A, 0172A: April 18, 2023	CPT® 2024



	moorporation of Non-Abbre		0 /	•
			Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023	
# ** •91308	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use ▶ (Report 91308 with administration codes 0081A, 0082A, 0083A) ◀ ▶ (Do not report 91308 in conjunction with administration codes 0001A, 0002A, 0003A, 0004A, 0051A, 0052A, 0053A, 0054A, 0071A, 0072A, 0073A, 0074A, 0121A, 0124A, 0151A, 0154A, 0171A, 0172A, 0173A, 0174A) ◀	February 1, 2022 April 26, 2022 June 7, 2022 August 31, 2022 December 9, 2022 March 17, 2023 Revised Parenthetical Note Released to AMA Website May 1, 2023	0001A, 0002A: December 11, 2020 0003A: August 12, 2021 0004A: September 22, 2021 0051A, 0052A, 0053A, 0054A, 0071A, 0072A: October 29, 2021 0073A: January 23, 2022 0074A: May 17, 2022 0081A, 0082A, 0083A, 91308: June 17, 2022 0124A: August 31, 2022 0154A: October 12, 2022 0173A: December 8, 2022 0174A: March 14, 2023 Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023	CPT® 2023/2024
# • 91317	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2	December 9, 2022	0001A, 0002A:- December 11, 2020	CPT® 2024



	mL dosage, diluent reconstituted, tris-sucrose formulation,	New Parenthetical	0003A: August 12,	
	for intramuscular use	Note Released to	2021	
	► (Report 91317 with administration codes 0171A, 0172A,	AMA Website	00044. Cantambar	
	0173A <u>, 0174A</u>)◀	March 47, 2022	0004A: September	
		March 17, 2023	22, 2021	
	► (Use 91317 only as the third dose in the primary series,	Boyland	00514 00524	
	with the first two doses reported using 91308, 0081A,	Revised	0051A, 0052A,	
	0082A)◀	Parenthetical	0053A, 0054A,	
	►(Use 91317 as the booster <u>additional</u> dose in the primary	Note Released to	0071A, 0072A:	
	series, with the first three doses reported using 91308, 0081A, 0082A, 0083A)◀	AMA Website	October 29, 2021 0073A: January 3,	
	► (Do not report 91317 in conjunction with administration	May 1, 2023	2022	
	codes 0001A, 0002A, 0003A, 0004A, 0051A, 0052A, 0053A, 0054A, 0071A, 0072A, 0073A, 0074A, 0081A,		0074A: May 17, 2022	
	0082A, 0083A, <u>0121A,</u> 0124A, <u>0151A,</u> 0154A)◀		0081A, 0082A, 0083A: June 17, 2022	
			0124A: August 31, 2022	
			0154A: October 12, 2022	
			0173A, 91317: December 8, 2022	
			0174A: March 14, 2023	
			0121A, 0151A, 0171A, 0172A: April 18, 2023	
			Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023	
# ● 91301	Severe acute respiratory syndrome coronavirus 2 (SARS-	November 10, 2020	0011A, 0012A,	CPT®
	CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use	August 16, 2021	91301: December 18, 2020	2022/2023/2024
	► (Report 91301 with administration codes 0011A, 0012A, 0013A) ◀	New Parenthetical Note Released to	0013A: August 12, 2021	
	► (Do not report 91301 in conjunction with administration codes 0064A, 0091A, 0092A, 0093A, 0094A, 0111A,	AMA Website	0064A: October 20, 2021	
	0112A, 0113A, 0134A, 0141A, 0142A, 0144A, 0164A)◀	May 19, 2022		
	,,,,,,,,,,,,,,,,,,,,,	July 6, 2022	0094A: March 29, 2022	
		August 31, 2022	0091A, 0092A,	
		November 16, 2022	0093A, 0111A, 0112A, 0113A:	



		1	-	
	·	Revised Parenthetical Note Released to AMA Website May 1, 2023	June 17, 2022 0134A (18 years and older): August 31, 2022 0134A (12 years through 17 years), 0144A: October 12, 2022 0164A: December 8, 2022 0141A, 0142A: April 18, 2023 Highlighted and	
			stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023	
# .≁ •91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use ► (Report 91306 with administration code 0064A) ◄ ► (Do not report 91306 in conjunction with administration codes 0011A, 0012A, 0013A, 0091A, 0092A, 0093A, 0094A, 0111A, 0112A, 0113A, 0134A, 0141A, 0142A, 0144A, 0164A) ◀	New Parenthetical Note Released to AMA Website May 19, 2022 July 6, 2022 August 31, 2022 November 16, 2022 Revised Parenthetical Note Released to AMA Website May 1, 2023	0011A, 0012A: December 18, 2020 0013A: August 12, 2021 0064A, 91306: October 20, 2021 0094A: March 29, 2022 0091A, 0092A, 0093A, 0111A, 0112A, 0113A: June 17, 2022 0134A (18 years and older): August 31, 2022 0134A (12 years through 17 years), 0144A: October 12, 2022 0164A: December 8, 2022 0141A, 0142A: April 18, 2023 Highlighted and	CPT® 2023/2024
			stricken codes in the	



	moorporation of Atom Atomic			•
			Effective column are no longer authorized for use in the United States as of April 18, 2023	
# * •91313	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use ▶ (Report 91313 with administration code 0134A) ◀ ▶ (Do not report 91313 in conjunction with administration codes 0011A, 0012A, 0013A, 0064A, 0091A, 0092A, 0093A, 0094A, 0111A, 0112A, 0113A, 0141A, 0142A, 0144A, 0164A) ◀	August 31, 2022 November 16, 2022 Revised Parenthetical Note Released to AMA Website May 1, 2023	0011A, 0012A: December 18, 2020 0013A: August 12, 2021 0064A: October 20, 2021 0094A: March 29, 2022 0091A, 0092A, 0093A, 0111A, 0112A, 0113A: June 17, 2022 0134A and 91313 (18 years and older): August 31, 2022 0134A (12 years through 17 years); October 12, 2022 0144A, 91313 (12 years through 17 years): October 12, 2022 0164A: December 8, 2022 0141A, 0142A: April 18, 2023 Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023	CPT® 2024
#₩●91314	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use ▶ (Report 91314 with administration codes 0141A, 0142A, 0144A) ◀ ▶ (Do not report 91314 in conjunction with administration	August 31, 2022 November 16, 2022 Revised Parenthetical Note Released to AMA Website	0011A, 0012A:- December 18, 2020 0013A: August 12, 2021 0064A: October 20, 2021	CPT® 2024
	codes 0011A, 0012A, 0013A, 0064A, 0091A, 0092A, 0093A, 0094A, 0111A, 0112A, 0113A, 0134A, 0164A)◀	May 1, 2023	0094A: March 29, 2022	

31



-		1	T	T
			0091A, 0092A, 0093A, 0111A, 0112A, 0113A: June 17, 2022 0134A (12 years through 17 years), 0144A, 91314: October 12, 2022 0164A: December 8, 2022 0141A, 0142A: April 18, 2023 Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023	
# *** 91311	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use ▶ (Report 91311 with administration codes 0111A, 0112A, 0113A) ◀ ▶ (Do not report 91311 in conjunction with administration codes 0011A, 0012A, 0013A, 0064A, 0091A, 0092A, 0093A, 0094A, 0134A, 0141A, 0142A, 0144A, 0164A) ◀	May 19, 2022 July 6, 2022 August 31, 2022 November 16, 2022 Revised Parenthetical Note Released to AMA Website May 1, 2023	0064A: October 20, 2021 0094A: March 29, 2022 0091A, 0092A, 0093A, 0111A, 0112A, 0113A, 91311: June 17, 2022 0134A (18 years and older): August 31, 2022 0134A (12 years through 17 years), 0144A: October 12, 2022 0164A: December 8, 2022 0141A, 0142A: April 18, 2023 Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023	CPT® 2023/2024



# . ●91316	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use ▶ (Report 91316 with administration code 0164A) ◀ ▶ (Do not report 91316 in conjunction with administration codes 0011A, 0012A, 0013A, 0064A, 0091A, 0092A, 0093A, 0094A, 0111A, 0112A, 0113A, 0134A, 0141A, 0142A, 0144A) ◀	Revised Parenthetical Note Released to AMA Website May 1, 2023	0011A, 0012A: December 18, 2020 0013A: August 12, 2021 0064A: October 20, 2021 0094A: March 29, 2022 0091A, 0092A, 0093A, 0111A, 0112A, 0113A: June 17, 2022 0134A (18 years and older): August 31, 2022 0134A (12 years through 17 years), 0144A: October 12, 2022 0164A, 91316: December 8, 2022 0164A, 91316: December 8, 2022 0141A, 0142A: April 18, 2023 Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023	CPT® 2024
# . ◆ 91309	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use ▶ (Report 91309 with administration codes 0091A, 0092A, 0093A, 0094A) ◀ ▶ (Do not report 91309 in conjunction with administration codes 0011A, 0012A, 0013A, 0064A, 0111A, 0112A, 0113A, 0134A, 0141A, 0142A, 0144A, 0164A) ◀	March 7, 2022 May 19, 2022 July 6, 2022 August 31, 2022 November 16, 2022 Revised Parenthetical Note Released to AMA Website	0011A, 0012A: December 18, 2020 0013A: August 12, 2021 0064A: October 20, 2021 0094A, 91309: March 29, 2022 0091A, 0092A, 0093A, 0111A,	CPT [®] 2023/2024



	moorporation of Non Albert		O 7	•
			and older): August 31, 2022	
			0134A (12 years through 17 years), 0144A: October 12, 2022	
			0164A: December 8, 2022	
			0141A, 0142A: April 18, 2023	
			Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023	
# ₩◆91302	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 ¹⁰ viral particles/0.5 mL dosage, for intramuscular use ▶ (Report 91302 with administration codes 0021A, 0022A) ◀	December 17, 2020	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2022
#• 91303	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5 mL dosage, for intramuscular use	January 19, 2021 October 27, 2021	0031A, 91303: February 27, 2021 0034A: October 20, 2021	CPT [®] 2022/2023
	► (Report 91303 with administration codes 0031A. 0034A) ◀		No longer authorized for use in the United States as of June 1, 2023	
# */ •91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use	May 4, 2021 July 26, 2022 October 10, 2022	0041A, 0042A, 91304: July 13, 2022 0044A: October 19, 2022	CPT [®] 2022/2023
	► (Report 91304 with administration codes 0041A, 0042A, 0044A) ◀			
# ∦ ◆91310	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use ► (Report 91310 with administration code 0104A) ◄	April 26, 2022	Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration	CPT [®] 2023



90476	Adenovirus vaccine, type 4, live, for oral use			
96372	Hydration, Therapeutic, Prophylactic, Diagnostic Injections and Infusions, and Chemotherapy and Other Highly Complex Drug or Highly Complex Biologic Agent Administration	Revised Parenthetical Note Released to AMA Website	Revised Parenthetical Note Effective	Revised Parenthetical Note Publication
			0001A, 0002A: December 11, 2020 0011A, 0012A: December 18, 2020 0031A: February 27, 2021 0003A, 0013A: August 12, 2021 0004A: September 22, 2021 0051A, 0052A, 0053A, 0054A, 0071A, 0072A: October 20, 2021 0073A: January 3, 2022 0074A: March 29, 2021 0074A: May 17, 2022 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0091A, 0092A, 0093A, 0111A, 0112A, 0113A: June 17, 2022 0041A, 0042A: July 13, 2022 0124A, 0134A (18 years and older): August 31, 2022 0134A (12 years	
			through 17 years), 0144A, 0154A: October 12, 2022	



		0044A: October 19, 2022 0164A, 0173A: December 8, 2022 0174A: March 14,	
		2023 0121A, 0141A,	
		0142A, 0151A, 0171A, 0172A: April 18, 2023	
		Highlighted and stricken codes in the Effective column are no longer authorized for use in the United States as of April 18, 2023	
		0021A, 0022A, 0104A: Effective upon receiving Emergency Use Authorization or	
		approval from the Food and Drug Administration	
Appendix Q Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])	New Appendix Q Released to AMA Website	Appendix Q Effective	Appendix Q Publication
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccines This table links the individual severe acute respiratory	Released to AMA		
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccines This table links the individual severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine product codes (91300-9131791316913159131191310, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309) to their	Released to AMA Website November 10, 2020 Revised AppendixQ Released to	Effective 0001A, 0002A, 91300:	Publication CPT®
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccines This table links the individual severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine product codes (91300-9131791316913159131191310, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309) to their associated immunization administration codes (0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A,	Released to AMA Website November 10, 2020 Revised AppendixQ	0001A, 0002A, 91300:- December 11, 2020 0011A, 0012A, 91301:- December 18, 2020 0031A, 91303: February 27, 2021	Publication CPT®
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccines This table links the individual severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine product codes (91300-9131791316913159131191310, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309) to their associated immunization administration codes (0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A,	Released to AMA Website November 10, 2020 Revised AppendixQ Released to AMA Website December 17,	0001A, 0002A, 91300:- December 11, 2020 0011A, 0012A, 91301:- December 18, 2020 0031A, 91303: February 27, 2021 0003A, 0013A: August 12, 2021	Publication CPT®
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccines This table links the individual severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine product codes (91300-9131791316913159131191310, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309) to their associated immunization administration codes (0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A), patient age, manufacturer name, vaccine name(s), 10- and 11-digit National Drug	Released to AMA Website November 10, 2020 Revised AppendixQ Released to AMA Website December 17, 2020 January 19, 2021 May 4, 2021	0001A, 0002A, 91300:- December 11, 2020 0011A, 0012A, 91301:- December 18, 2020 0031A, 91303: February 27, 2021	Publication CPT®
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccines This table links the individual severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine product codes (91300-9131791316913159131191310, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309) to their associated immunization administration codes (0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A), patient age, manufacturer	Released to AMA Website November 10, 2020 Revised AppendixQ Released to AMA Website December 17, 2020 January 19, 2021	0001A, 0002A, 91300:- December 11, 2020 0011A, 0012A, 91301:- December 18, 2020 0031A, 91303: February 27, 2021 0003A, 0013A: August 12, 2021 0004A: September 22, 2021 0034A, 0064A, 91306:	Publication CPT®
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccines This table links the individual severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine product codes (91300-9131791316913159131191310, 91301, 91302, 91303, 91304, 91305, 91306, 91307, 91308, 91309) to their associated immunization administration codes (0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0021A, 0022A, 0031A, 0034A, 0041A, 0042A, 0044A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A, 0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A, 0164A, 0171A, 0172A, 0173A, 0174A), patient age, manufacturer name, vaccine name(s), 10- and 11-digit National Drug Code (NDC) Labeler Product ID, and interval between doses. These codes are also located in the Medicine	Released to AMA Website November 10, 2020 Revised AppendixQ Released to AMA Website December 17, 2020 January 19, 2021 May 4, 2021 July 30, 2021	0001A, 0002A, 91300:- December 11, 2020 0011A, 0012A, 91301:- December 18, 2020 0031A, 91303: February 27, 2021 0003A, 0013A: August 12, 2021 0004A: September 22, 2021	Publication CPT®



0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0104A, 0111A, 0112A, 0113A, 0121A,	October 27, 2021	0071A, 0072A, 91305, 91307:
0124A, 0134A, 0141A, 0142A, 0144A, 0151A, 0154A,	January 12, 2022	October 29, 2021
0164A, 0171A, 0172A, 0173A, 0174A and 91300- 9131791316913159131191310, 91301, 91302, 91303,	February 1, 2022	0073A:
91304, 91305, 91306, 91307, 91308, 91309 can be found in	-	January 3, 2022
the Immunization Administration for Vaccines/Toxoids and Vaccines, Toxoids guidelines in the Medicine section	March 7, 2022	0094A, 91309:-
of the CPT code set.	April 26, 2022	March 29, 2022
	May 19, 2022	0074A: May 17, 2022
	June 7, 2022	
	July 6, 2022	0081A, 0082A, 0083A, 0091A,
	August 31, 2022	0092A, 0093A, 0111A, 0112A, 0113A, 91308,
	October 10, 2022	91311: June 17, 2022
	November 16, 2022	
	December 9, 2022	0041A, 0042A, 91304:
	March 17, 2023	July 13, 2022
	May 1, 2023	0124A, 0134A (18 years and older):
		August 31, 2022
		0134A (12 years
		through 17 years), 0144A, 0154A,
		91315: October 12, 2022
		0044A: October 19, 2022
		0164A, 0173A,
		91316, 91317: December 8, 2022
		0174A: March 14,
		2023
		0121A, 0141A,
		0142A, 0151A, 0171A, 0172A:
		April 18, 2023
		Highlighted and
		stricken codes in the Effective column are
		no longer authorized for use in the United
		States as of April 18,
		2023



	0021A, 0022A,
	0104A, 91302,
	91310: Effective
	upon receiving
	Emergency Use
	Authorization or
	approval from the
	Food and Drug
	Administration



	Vaccine Code	Vaccine Administration Code(s)	Patient Age	Vaccine Manufacturer	Vaccine Name(s)	NDC 10/NDC 11 Labeler Product ID (Vial)	Dosing Interval
#• 91300	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted, for intramuscular use	●0001A (1st Dose) ●0002A (2nd Dose) ●0003A (3rd Dose) ●0004A (Booster)	12 years and older	Pfizer, Inc	Pfizer-BioNTech COVID-19 Vaccine/ <u>Comirnaty</u>	59267-1000-1 59267-1000-01	2nd Dose to 2nd Dose: 21 Days 2nd Dose to 3rd Dose (CDC-recommended population[s] [eq. immunocompromised]): 28 or More Days Booster All Dosing: Refer to FDA/CDC Guidance
# .≁. •91305	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	#●0051A (1st Dose) #●0052A (2nd Dose) #●0053A (3rd Dose) #●0054A (Booster)	12 years and older	Pfizer, Inc	Pfizer-BioNTech COVID-19 Vaccine/Comirnaty	59267-1025-1 59267-1025-01 00069-2025-1 00069-2025-01	2nd Dose to 2nd Dose: 21 Days 2nd Dose to 3rd Dose (CDC- recommended population[s] [eg. immunocompromised]): 28 or More Days Booster All Dosing: Refer to FDA/CDC Guidance
# * ●9131	2 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	#●0121A (1st Dose) #▲●0124A (Beoster-Additional Dose)	12 years and older	Pfizer, Inc	Pfizer-BioNTech COVID-19 Bivalent	59267-0304-1 59267-0304-01 59267-1404-1 59267-1404-01	Booster-All Dosing: Refer to FDA/CDC Guidance



Vaccine Code	Vaccine Administration Code(s)	Patient Age	Vaccine Manufacturer	Vaccine Name(s)	NDC 10/NDC 11 Labeler Product ID (Vial)	Dosing Interval
## 91307 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	#●0071A (1st Dose) #●0072A (2nd Dose) #●0073A (3rd Dose) #●0074A (Booster)	5 years through 11 years	Pfizer, Inc	Pfizer-BioNTech COVID-19 Vaccine	<u>59267-1055-1</u> <u>59267-1055-01</u>	1st Dose to 2nd Dose: 21 Days 2nd Dose to 3rd Dose (CDC- recommended population[s] [eq. immunocompromised]) 28 or More Days Booster-All Dosing: Refer to FDA/CDC Guidance
## •91315 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	#●0151A (1st Dose) #▲●0154A (Booster-Additional Dose)	5 years through 11 years	Pfizer, Inc	Pfizer-BioNTech COVID-19 Bivalent	59267-0565-1 59267-0565-01	Beester All Dosing: Refer to FDA/CDC Guidance
## 91308 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	#●0081A (1st Dose) #●0082A (2nd Dose) #●0083A (3rd Dose)	6 months through 4 years	Pfizer, Inc	Pfizer-BioNTech COVID-19 Vaccine	59267-0078-1 59267-0078-01 59267-0078-4 59267-0078-04	1st Dose to 2nd Dose: 21 Days 2nd Dose to 3rd Dose All Dosing: Refer to FDA/CDC Guidance



	Vaccine Code	Vaccine Administration Code(s)	Patient Age	Vaccine Manufacturer	Vaccine Name(s)	NDC 10/NDC 11 Labeler Product ID (Vial)	Dosing Interval
# ●91317	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	#●0171A (1st Dose) #●0172A (2nd Dose) #▲●0173A (3rd Dose) #▲●0174A (Beoster Additional Dose)	6 months through 4 years	Pfizer, Inc	Pfizer-BioNTech COVID-19 Bivalent	59267-0609-1 59267-0609-01	3 rd Dose: Refer to FDA/CDC Guidance Beester All Dosing: Refer to FDA/CDC Guidance
#● 91301	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage, for intramuscular use	●0011A (1st Dose) ●0012A (2nd Dose) ●0013A (3rd Dose)	1812 years and older	Moderna, Inc	Moderna COVID-19 Vaccine/ <u>spikevax</u>	80777-273-10 80777-0273-10 80777-100-11 80777-0100-11	1st Dose to 2nd Dose: 28 Days 2nd Dose to 3rd Dose (CDC recommended population[s] [eq. immunocompromised]): 28 or More Days Booster-All Dosing: Refer to FDA/CDC Guidance
#. → 91306	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	# ● 0064A (Booster)	18 years and older	Moderna, Inc	Moderna COVID-19 Vaccine	80777-273-10 80777-0273-10	Refer to FDA/CDC Guidance All Dosing: Refer to FDA/CDC Guidance
# ₩•91313	Severe acute respiratory syndrome coronavirus 2	#▲●0134A (Booster Additional Dose)	1812 years and older	Moderna, Inc	<u>Moderna</u>	80777-282-05 80777-0282-05	



Vaccine Code	Vaccine Administration Code(s)	Patient Age	Vaccine Manufacturer	Vaccine Name(s)	NDC 10/NDC 11 Labeler Product ID (Vial)	Dosing Interval
(SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use		12 years through 17 years: Effective upon receiving Emergency Use Authorization or approval from the Food and Drug Administration		COVID-19 Vaccine, Bivalent		Booster-Additional Dose: Referto FDA/CDC Guidance
##•91314 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	#●0141A (1st Dose) #●0142A (2nd Dose) #▲●0144A (Booster-Additional Dose)	6 months years through 11 years	Moderna, Inc	Moderna COVID-19 Vaccine, Bivalent	80777-282-05 80777-0282-05	Beester All Dosing: Refer to FDA/CDC Guidance
## •91311 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	●0111A (1st Dose) ●0112A (2nd Dose) ●0113A (3rd Dose)	6 months through 5 years	Moderna, Inc	Moderna COVID-19 Vaccine	80777-279-05 80777-0279-05	1st Dose to 2nd Dose: 1 Month 2nd Dose to 3rd Dose (CDC- recommended population[s] [eg. immunocompromised]): 1



Vaccine Code	Vaccine Administration Code(s)	Patient Age	Vaccine Manufacturer	Vaccine Name(s)	NDC 10/NDC 11 Labeler Product ID (Vial)	Dosing Interval
##•91316 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL10 mcg/0.2 mL dosage, for intramuscular use	▲ ● 0164A (Beester Additional Dose)	6 months through 5 years	Moderna, Inc	Moderna COVID-19 Vaccine, Bivalent	80777-283-02 80777-0283-02	Beoster-Additional Dose: Refer to FDA/CDC Guidance
## 91309 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	●0091A (1st Dose) ●0092A (2nd Dose) ●0093A (3rd Dose)	6 years through 11 years	Moderna, Inc	Moderna COVID-19 Vaccine	80777-275-05 80777-0275-05	1st Dose to 2nd Dose: 1 Month 2nd Dose to 3rd Dose (CDC-recommended population[s] [eg. immunocompromised]): 1 Month All Dosing: Refer to FDA/CDC-Guidance
	<u># ▲ </u>	18 years and older	Moderna, Inc	Moderna COVID-19 Vaccine	80777-275-05 80777-0275-05	Booster: Refer to FDA/CDC Guidance All Dosing: Refer to FDA/CDC Guidance
# № ●91302 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10 ¹⁰ viral particles/0.5 mL dosage, for intramuscular use	●0021A (1st Dose) ●0022A (2nd Dose)	18 years and older	AstraZeneca, Plc	AstraZeneca COVID-19 Vaccine	0310-1222-10 00310-1222-10	28 Days

CPT © Copyright 2023 American Medical Association.

All rights reserved. AMA and CPT are registered trademarks of the American Medical Association.

Updated August 2, 2023



	Vaccine Code	Vaccine Administration Code(s)	Patient Age	Vaccine Manufacturer	Vaccine Name(s)	NDC 10/NDC 11 Labeler Product ID (Vial)	Dosing Interval
#● 91303	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5 mL dosage, for intramuscular use	▲●0031A (Single Dose) ●0034A (Booster)	18 years and older	Janssen	Janssen COVID-19 Vaccine	59676-580-05 59676-0580-05	Not Applicable Booster: Refer to FDA/CDC Guidance All Dosing: Refer to FDA/CDC Guidance
#, ●91304	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use	●0041A (1st Dose) ●0042A (2nd Dose)	1812 years and older	Novavax, Inc	Novavax COVID-19 Vaccine	80631-100-01 80631-1000-01	21 Days
		● <u>0044A (Booster)</u>	18 years and older	Novavax, Inc	Novavax COVID-19 Vaccine	80631-100-01 80631-1000-01	Booster: Refer to FDA/CDC Guidance
# № •91310	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, monovalent, preservative free, 5 mcg/0.5 mL dosage, adjuvant AS03 emulsion, for intramuscular use	●0104A (Booster)	18 years and older	Sanofi Pasteur	Sanofi Pasteur COVID-19 Vaccine, (Adjuvanted For Booster Immunization)	<u>49281-618-20</u> 49281-0618-20	Booster: Refer to FDA/CDC Guidance

Updated August 2, 2023